Information  X 
Enter a valid email address

Alliance Pharma PLC (APH)

  Print      Mail a friend       Annual reports

Friday 10 August, 2018

Alliance Pharma PLC

Total Voting Rights

RNS Number : 4669X
Alliance Pharma PLC
10 August 2018

For immediate release

10 August 2018



("Alliance" or the "Company")


Total Voting Rights


Alliance Pharma plc (AIM: APH), the specialty pharmaceutical group, makes the following notification in accordance with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1.


As at 31 July 2018 the Company's issued share capital consists of 515,127,294 Ordinary Shares of 1p each.


The total number of voting rights in the Company is 515,127,294 and this figure may be used by shareholders as the denominator for the calculations by which they should determine if they are required to notify their interest in, or change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.



For further information:


Alliance Pharma plc                                                                                         

Peter Butterfield, Chief Executive Officer

Andrew Franklin, Chief Financial Officer


+ 44 (0) 1249 466966


Mark Court / Sophie Wills / Gemma Mostyn-Owen


+ 44 (0) 20 7466 5000

Numis Securities Limited                                            

Nominated Adviser: Michael Meade / Freddie Barnfield

Corporate Broking: James Black / Toby Adcock


+ 44 (0) 20 7260 1000

Investec Bank plc                                                                                              

Corporate Finance: Daniel Adams / Ed Thomas

Corporate Broking: Patrick Robb / Rob Baker


+44 (0) 20 7597 5970


Notes to editors:


About Alliance Pharma


Alliance, founded in 1998, is an international specialty pharmaceutical group based in Chippenham, Wiltshire, UK. The Group has sales in more than 100 countries worldwide via direct sales, joint ventures and a wide network of distributors.  Alliance has a strong track record of acquiring the rights to established niche products and it currently owns or licenses the rights to approximately 90 pharmaceutical and consumer healthcare products. The Group continues to explore opportunities to expand its product portfolio.


Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

a d v e r t i s e m e n t